[go: up one dir, main page]

WO2007083119A3 - Methods - Google Patents

Methods Download PDF

Info

Publication number
WO2007083119A3
WO2007083119A3 PCT/GB2007/000146 GB2007000146W WO2007083119A3 WO 2007083119 A3 WO2007083119 A3 WO 2007083119A3 GB 2007000146 W GB2007000146 W GB 2007000146W WO 2007083119 A3 WO2007083119 A3 WO 2007083119A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
patient
statin
cachexia
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2007/000146
Other languages
French (fr)
Other versions
WO2007083119A2 (en
Inventor
Stephan Anker
Stephen Von Haehling
Jochen Springer
Thomas Thum
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ip2ipo Innovations Ltd
Original Assignee
Imperial Innovations Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imperial Innovations Ltd filed Critical Imperial Innovations Ltd
Priority to AU2007206776A priority Critical patent/AU2007206776A1/en
Priority to JP2008550841A priority patent/JP2009523778A/en
Priority to EP07704928A priority patent/EP1973542A2/en
Publication of WO2007083119A2 publication Critical patent/WO2007083119A2/en
Publication of WO2007083119A3 publication Critical patent/WO2007083119A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The use of at least one statin in the manufacture of a medicament for the prevention or treatment of cachexia in a patient, wherein the patient is human or a domestic or farm animal
PCT/GB2007/000146 2006-01-18 2007-01-18 Methods Ceased WO2007083119A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2007206776A AU2007206776A1 (en) 2006-01-18 2007-01-18 Methods
JP2008550841A JP2009523778A (en) 2006-01-18 2007-01-18 Method
EP07704928A EP1973542A2 (en) 2006-01-18 2007-01-18 Treatment of cachexia with statins

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0600967.4A GB0600967D0 (en) 2006-01-18 2006-01-18 Methods
GB0600967.4 2006-01-18

Publications (2)

Publication Number Publication Date
WO2007083119A2 WO2007083119A2 (en) 2007-07-26
WO2007083119A3 true WO2007083119A3 (en) 2008-03-20

Family

ID=36010486

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2007/000146 Ceased WO2007083119A2 (en) 2006-01-18 2007-01-18 Methods

Country Status (5)

Country Link
EP (1) EP1973542A2 (en)
JP (1) JP2009523778A (en)
AU (1) AU2007206776A1 (en)
GB (1) GB0600967D0 (en)
WO (1) WO2007083119A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009121623A2 (en) * 2008-04-04 2009-10-08 Summit Corporation Plc Compounds for treating muscular dystrophy
EP2905029B1 (en) 2012-10-04 2018-11-21 Shionogi&Co., Ltd. Drug for inhibiting malignant tumor metastasis
EP2832357A1 (en) * 2013-07-29 2015-02-04 Charité - Universitätsmedizin Berlin Selective AT2 receptor agonists for use in treatment of cachexia
EA201992215A1 (en) 2017-03-20 2020-02-06 Форма Терапьютикс, Инк. Pyrrolopyrrole Compositions as Pyruvate Kinase Activators (PKR)
EP3852791B1 (en) 2018-09-19 2024-07-03 Novo Nordisk Health Care AG Activating pyruvate kinase r
US10675274B2 (en) 2018-09-19 2020-06-09 Forma Therapeutics, Inc. Activating pyruvate kinase R
WO2021055807A1 (en) 2019-09-19 2021-03-25 Forma Therapeutics, Inc. Activating pyruvate kinase r
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003007993A1 (en) * 2001-07-19 2003-01-30 Pharmacia Corporation Combination of an aldosterone receptor antagonist and an hmg coa reductase inhibitor

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003007993A1 (en) * 2001-07-19 2003-01-30 Pharmacia Corporation Combination of an aldosterone receptor antagonist and an hmg coa reductase inhibitor

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
ANKER STEFAN D ET AL: "Statin use and survival in patients with chronic heart failure--results from two observational studies with 5200 patients.", INTERNATIONAL JOURNAL OF CARDIOLOGY 20 SEP 2006, vol. 112, no. 2, 20 September 2006 (2006-09-20), pages 234 - 242, XP002464984, ISSN: 1874-1754 *
DAVIS M P ET AL: "Cachexia and anorexia: cancer's covert killer.", SUPPORTIVE CARE IN CANCER : OFFICIAL JOURNAL OF THE MULTINATIONAL ASSOCIATION OF SUPPORTIVE CARE IN CANCER MAY 2000, vol. 8, no. 3, May 2000 (2000-05-01), pages 180 - 187, XP002464985, ISSN: 0941-4355 *
MAHMOUD F A ET AL: "The role of C-reactive protein as a prognostic indicator in advanced cancer", CURRENT ONCOLOGY REPORTS, CURRENT SCIENCE, GB, vol. 4, no. 3, May 2002 (2002-05-01), pages 250 - 255, XP008087414, ISSN: 1523-3790 *
MUSCARITOLI MAURIZIO ET AL: "Effects of simvastatin administration in an experimental model of cancer cachexia.", NUTRITION (BURBANK, LOS ANGELES COUNTY, CALIF.) 2003 NOV-DEC, vol. 19, no. 11-12, November 2003 (2003-11-01), pages 936 - 939, XP002464981, ISSN: 0899-9007 *
PITT B ET AL: "Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II.", LANCET 6 MAY 2000, vol. 355, no. 9215, 6 May 2000 (2000-05-06), pages 1582 - 1587, XP002464986, ISSN: 0140-6736 *
PITT B ET AL: "Effects of losartan versus captopril on mortality in patients with symptomatic heart failure: rationale, design, and baseline characteristics of patients in the Losartan Heart Failure Survival Study--ELITE II.", JOURNAL OF CARDIAC FAILURE JUN 1999, vol. 5, no. 2, June 1999 (1999-06-01), pages 146 - 154, XP002464987, ISSN: 1071-9164 *
RIDKER P M ET AL: "Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators.", CIRCULATION 20 JUL 1999, vol. 100, no. 3, 20 July 1999 (1999-07-20), pages 230 - 235, XP002464983, ISSN: 1524-4539 *
SASAKI MAKOTO ET AL: "The 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor pravastatin reduces disease activity and inflammation in dextran-sulfate induced colitis.", THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS APR 2003, vol. 305, no. 1, April 2003 (2003-04-01), pages 78 - 85, XP002464982, ISSN: 0022-3565 *

Also Published As

Publication number Publication date
WO2007083119A2 (en) 2007-07-26
AU2007206776A1 (en) 2007-07-26
JP2009523778A (en) 2009-06-25
EP1973542A2 (en) 2008-10-01
GB0600967D0 (en) 2006-03-01

Similar Documents

Publication Publication Date Title
WO2007083119A3 (en) Methods
WO2006096793A3 (en) Medical implants
WO2006102374A3 (en) Bioactive wide-weave mesh
WO2010014690A3 (en) Medical devices for therapeutic agent delivery
WO2008137780A3 (en) Use of [3.2.0] heterocyclic compounds and analogs thereof for treating infectious diseases
WO2008073670A3 (en) Unit dose formulations and methods of treating thrombosis with an oral factor xa inhibitor
ATE456369T1 (en) FLIBANSERIN FOR THE TREATMENT OF URINARY INCONTINENCE AND ASSOCIATED DISEASES
WO2010048087A3 (en) Compositions and methods for treating periodontal disease comprising clonidine, sulindac and/or fluocinolone
EP2056865A4 (en) Novel drug target of preventing and treating periodontal disease, improving healing of periodontal wounds and promoting oral health
EP2091480A4 (en) System for the treatment of heart tissue
WO2009103959A3 (en) Histidine and/or histidine derivative for the treatment of inflammatory skin diseases
IL213703A (en) Compounds for the treatment of pain and other diseases
IL186022A0 (en) Dermatological compositions and salts for the treatment of dermatological diseases
EP2278981A4 (en) Biological markers and response to treatment for pain, inflammation, neuronal or vascular injury and methods of use
EP2716285A3 (en) New method for identifying compounds useful for treating and/or preventing diseases associated with bone loss
WO2007137301A3 (en) Modulation of chrebp expression
GB2435425B (en) Medical wound healing treatment
WO2008011473A3 (en) Compositions and their uses directed to hbxip
WO2008009655A3 (en) Medical use of n-phenylpropenoyl-amino acid derivatives and related compounds
WO2007025229A3 (en) Compositions and their uses directed to hsp27
GB0524514D0 (en) Medical wound healing treatment
WO2009007112A3 (en) Thrombomodulin for increasing reperfusion and preventing blood vessels obstruction
WO2006117624A3 (en) Kynurenic acid and salts thereof for the prevention and treatment of shock
WO2009025091A1 (en) Pharmaceutical composition for treatment of fibromyalgia
WO2007054566A3 (en) Use of fenofibrate or a derivative thereof for preventing diabetic retinopathy

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2008550841

Country of ref document: JP

Ref document number: 2007704928

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007206776

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2007206776

Country of ref document: AU

Date of ref document: 20070118

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2007206776

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2007704928

Country of ref document: EP